Answers are grounded in this paper and cite their sources.
We aimed to evaluate the early functional, anatomical and safety outcomes of Anyra TM (Zydus Lifesciences Ltd., Ahmedabad, India), a novel aflibercept biosimilar (Afl-Bs), in treatment-naïve eyes with neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DME), retinal vein occlusion (RVO) or myopic macular neovascularization (MNV). This multicentre retrospective observational study included 162 consecutive treatment-naïve eyes from 162 patients treated with a single intravitreal injection of Afl-Bs at five tertiary retina centres in India between April 2026 and May 2026. The cohort comprised 82 eyes with nAMD, 40 eyes with DME, 36 eyes with RVO and 4 eyes with myopic MNV. Best-corrected visual acuity (BCVA), converted to logarithm of the minimum angle of resolution (logMAR), central macular thickness (CMT), intraretinal fluid (IRF), subretinal fluid (SRF) and complete retinal drying were evaluated at baseline and 1 month. Paired t -tests and McNemar tests were used, as appropriate. Mean BCVA improved from 0.77 ± 0.40 logMAR at baseline to 0.55 ± 0.39 logMAR at 1 month (mean difference, −0.22 ± 0.26 logMAR; P < 0.001). Mean CMT decreased from 480.67 ± 207.8 µm to 309.13 ± 163.4 µm (mean difference, −71.54 ± 170.8 µm; P < 0.001). IRF was present in 120 eyes (74.1%) at baseline and 40 eyes (24.7%) at 1 month ( P < 0.001); SRF decreased from 82 eyes (50.6%) to 33 eyes (20.4%) ( P < 0.001). Complete retinal drying was observed in 96 eyes (59.3%) at 1 month. Significant improvements in BCVA and CMT were observed across nAMD, DME and RVO subgroups. No ocular or systemic adverse events were observed during follow-up. Early multicentre real-world experience suggests that Afl-Bs provides favourable short-term functional and anatomical outcomes across common retinal diseases, with no unexpected adverse events documented during the study period. Larger prospective comparative studies with longer follow-up are warranted to further evaluate its clinical effectiveness and safety.
No takes yet. Share an insight, caveat, or question.
Chakraborty et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: